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cheaper, pose less risks to patients, and offer greater ben-
eﬁt by reducing infections due to many pathogens, not just
those due to MRSA.
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Prevention of Cytomegalovirus Infection after
Hematopoietic Stem Cell Transplantation: Preemptive
Therapy Vs Universal Prophylaxis
S. Mossad
Cleveland Clinic Foundation, Cleveland, OH, USA
Blood products administered to all HSCT recipients;
particularly those who are CMV seronegative, should be
leukocyte depleted, or obtained from CMV seronegative
donors.
Allogeneic HSCT recipients should be managed under
a CMV prevention strategy; either universal prophylaxis
or preemptive therapy for the ﬁrst 100 days. There are
advantages & disadvantages to both strategies. Intravenous
ganciclovir (GCV) or oral valganciclovir (VGCV) are the most
commonly used agents. Foscarnet & cidofovir are alterna-
tives, but both require prehydration & may be nephrotoxic.
Acyclovir & valacyclovir are much less active against CMV.
Universal prophylaxis with IV GCV or VGCV may cause neu-
tropenia, which can usually be managed with G-CSF and
temporary suspension of drug. Preemptive therapy requires
the ready availability of a sensitive test for early detec-
tion of asymptomatic CMV replication, such as antigenemia
or PCR. Such test should be done at least once weekly,
and treatment promptly initiated when test is positive, and
continued for at least for 2 weeks; longer if test is still
positive. Weekly surveillance testing should be continued
to detect recurrence. Patients who are CMV seropositive,
whose donors are CMV seronegative, or whose donors are
unrelated, haploidentical, cord blood, or T cell depleted, or
who develop CMV viremia < 100 days after HSCT, or steroid-
requiring chronic GVHD, or with CD4 counts < 50/mm3 are
at a higher risk for late CMV viremia occurring > 100 days
after HSCT. Such patients should be monitored with CMV
antigenemia or PCR for preemptive therapy.
Autologous HSCT who are CMV seropositive, and who are
at a higher risk for CMV reactivation due to total body irra-
diation, CD34+ selected T cell depleted grafts, or receipt
of alemtuzumab, ﬂudarabine, or 2-chlorodeoxyadenosine
in the 6 months preceding HSCT, should be monitored by
weekly CMV antigenemia or PCR for preemptive therapy for
60 days after HSCT.
doi:10.1016/j.ijid.2010.02.2222
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Engaging Nations in a Commitment to Infection Control
D. Pittet
University of Geneva Hospitals, Geneva, Geneva, Switzer-
landHealth care-associated infection is a major, global issue
for patient safety and its prevention was chosen by WHO
Patient Safety as the theme of its First Global Patient Safety
Challenge ‘‘Clean Care is Safer Care’’ launched in Octo-
ber 2005. Since then, a formal statement has been signedts e329
y over 120 ministries of health as a pledge of support to
mplement actions to reduce health care-associated infec-
ion, corresponding to more than 85% coverage of the world
opulation. The Challenge has focused on raising global
wareness of the importance of health care-associated
nfection as a priority patient safety issue with the promo-
ion of hand hygiene as the cornerstone.
The main output of the Challenge has been the devel-
pment of the WHO Guidelines on Hand Hygiene in Health
are and the design of an implementation strategy to trans-
ate the guidelines into practice. These have been tested
n eight pilot sites and used in over 350 healthcare settings
orldwide with very promising results. Over 40 countries
ave also established hand hygiene promotion campaigns
t national level. In August 2009, around 50 participants of
he ‘‘campaigning nations’’ network met in Geneva to share
nowledge, experiences and concerns, including approaches
o take account of cultural diversity.
The SAVE LIVES: Clean Your Hands initiative was also
aunched by WHO Patient Safety on 5 May 2009 to encour-
ge health-care workers to be part of a global movement
o improve and, importantly, sustain hand hygiene. More
han 5500 health-care facilities have already registered their
ommitment to the initiative with a target to achieve 10,000
egistrations by 5 May 2010. The ultimate aim of SAVE LIVES:
lean Your Hands is to demonstrate that hand hygiene is the
ssential basis for the reduction of health care-associated
nfection and to engage nations in a ﬁrm and ongoing com-
itment to infection prevention.
oi:10.1016/j.ijid.2010.02.2223
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nternational Controversies: Bare Below the Elbow and
he Incremental Value of MRSA Screening
. Edmond
Medical College of Virginia Campus, Richmond, VA, USA
This presentation will summarize the relevant data for
wo of the most controversial interventions to reduce
ealthcare associated infections. The ﬁrst half of the pre-
entation will lay out the arguments for why elimination
f white coats and adoption of a bare below the elbows
pproach should be considered for implementation. The sec-
nd half of the presentation will review problems associated
ith a MRSA search and destroy strategy and demon-
trate that horizontal strategies for infection prevention are
